Joseph Meletiadis
Overview
Explore the profile of Joseph Meletiadis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
166
Citations
3205
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
van den Berg S, Sassen S, Couet W, Marchand S, Van Der Spek H, Ten Kate M, et al.
J Antimicrob Chemother
. 2025 Mar;
PMID: 40036260
Background: Antibiotic combination therapy is increasingly used to treat MDR pathogens. In vitro studies suggest that the polymyxin B/rifampicin combination might be synergistic. Therefore, the pharmacodynamics of rifampicin as monotherapy...
2.
Cornely O, Sprute R, Bassetti M, Chen S, Groll A, Kurzai O, et al.
Lancet Infect Dis
. 2025 Feb;
PMID: 39956121
Candida species are the predominant cause of fungal infections in patients treated in hospital, contributing substantially to morbidity and mortality. Candidaemia and other forms of invasive candidiasis primarily affect patients...
3.
Kroustali V, Kanioura L, Resoulai E, Siopi M, Antonopoulou S, Meletiadis J
Microbiol Spectr
. 2025 Jan;
13(3):e0248824.
PMID: 39846759
The lack of clinical breakpoints and epidemiological cut-off values (ECOFFs) for antifungals prescribed for vulvovaginal candidiasis (VVC) make interpretation of antifungal susceptibility data difficult. This leads to empirical prescribing, poor...
4.
Kroustali V, Resoulai E, Kanioura L, Siopi M, Meletiadis J, Antonopoulou S
Mycoses
. 2025 Jan;
68(1):e70026.
PMID: 39834102
Background: The epidemiology of vulvovaginal candidiasis (VVC) in Greece remains poorly reported and outdated. Objectives: We therefore conducted a 2-year retrospective survey to assess the epidemiological aspects of the infection...
5.
van den Berg S, Attwood M, Griffin P, Sassen S, Muller A, Raaphorst M, et al.
J Antimicrob Chemother
. 2025 Jan;
80(3):752-759.
PMID: 39804217
Background: NOSO-5O2 is the first clinical candidate of a new antimicrobial class-the odilorhabdins. The pharmacodynamics of NOSO-502 were studied in vitro and in vivo to establish the pharmacodynamic index (PDI)...
6.
Paranos P, Pournaras S, Meletiadis J
Infect Dis Ther
. 2024 Dec;
14(1):217-228.
PMID: 39709574
Introduction: The host range of phages is usually assessed with the agar overlay method. However, this method is both cumbersome and subjective. Therefore, a microbroth assay was developed to assess...
7.
Abbott I, Anderson C, van Gorp E, Wallis S, Roberts J, Meletiadis J, et al.
J Antimicrob Chemother
. 2024 Dec;
80(2):413-426.
PMID: 39626168
Background: Catheter-associated urinary tract infections (CA-UTIs) are a common hospital-acquired infection. We examined ciprofloxacin activity in a novel CA-UTI in vitro model. Methods: Three ATCC strains [Escherichia coli (ECO)-25922, Klebsiella...
8.
Meletiadis J, Siopi M, Spruijtenburg B, Georgiou P, Kostoula M, Vourli S, et al.
Euro Surveill
. 2024 Nov;
29(45).
PMID: 39512169
After the start of the COVID-19 pandemic, a rapid rise in reported numbers and wide geographic spread of -related invasive infections has been observed globally. However, the contemporary epidemiology of...
9.
Mpakosi A, Cholevas V, Meletiadis J, Theodoraki M, Sokou R
Int J Mol Sci
. 2024 Sep;
25(17).
PMID: 39273215
Fungal colonization poses a significant risk for neonates, leading to invasive infections such as fungemia. While species are the most commonly identified pathogens, other rare yeasts are increasingly reported, complicating...
10.
Siopi M, Skliros D, Paranos P, Koumasi N, Flemetakis E, Pournaras S, et al.
Clin Microbiol Rev
. 2024 Jul;
37(3):e0004424.
PMID: 39072666
SUMMARYDespite the early recognition of their therapeutic potential and the current escalation of multidrug-resistant (MDR) pathogens, the adoption of bacteriophages into mainstream clinical practice is hindered by unfamiliarity with their...